BRNS – barinthus biotherapeutics plc - american depositary shares (US:NASDAQ)
Stock Stats
News
Barinthus Biotherapeutics plc (NASDAQ: BRNS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Barinthus Biotherapeutics GAAP EPS of -$1.55 misses by $0.25, revenue of $14.97M [Seeking Alpha]
Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments
Global Interferons Market is Predicted to Reach ~USD 14 Billion by 2032 | DelveInsight
Global Interferons Market is Predicted to Reach ~USD 14 Billion by 2032 | DelveInsight
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.